Par Drugs and Chemicals (NSE:PAR) Beneish M-Score: -2.57 (As of Jun. 26, 2026)


NSE:PAR Par Drugs and Chemicals Ltd NSE:PAR
74 GF Score
Price ₹91.00
GF Value ₹207.62
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Par Drugs and Chemicals Beneish M-Score?

Par Drugs and Chemicals NSE:PAR -1.80% 74 Beneish M-Score is -2.57 as of Jun. 26, 2026. GuruFocus rates NSE:PAR with a GF Score™ of 74/100 and a GF Value™ of ₹207.62 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 911 Drug Manufacturers companies, Par Drugs and Chemicals ranks better than 56.42% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.57 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Par Drugs and Chemicals's Beneish M-Score or its related term are showing as below:

NSE:PAR' s Beneish M-Score Range Over the Past 10 Years
Min: -3.08   Med: -2.56   Max: 10.44
Current: -2.57

During the past 10 years, the highest Beneish M-Score of Par Drugs and Chemicals was 10.44. The lowest was -3.08. And the median was -2.56.


Par Drugs and Chemicals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Par Drugs and Chemicals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Par Drugs and Chemicals Beneish M-Score Chart

Par Drugs and Chemicals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.90 -2.55 -3.08 10.44 -2.57

Par Drugs and Chemicals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.44 0.00 0.00 0.00 -2.57

NSE:PAR vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Par Drugs and Chemicals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Par Drugs and Chemicals Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Par Drugs and Chemicals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Par Drugs and Chemicals's Beneish M-Score falls into.


NSE:PAR
74GF Score
Par Drugs and Chemicals Ltd NSE:PAR
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Par Drugs and Chemicals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Par Drugs and Chemicals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7033+0.528 * 1.07+0.404 * 1.0003+0.892 * 1.0266+0.115 * 0.9453
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * -0.025722-0.327 * 0.7664
=-2.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹121 Mil.
Revenue was ₹1,037 Mil.
Gross Profit was ₹603 Mil.
Total Current Assets was ₹643 Mil.
Total Assets was ₹1,292 Mil.
Property, Plant and Equipment(Net PPE) was ₹372 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹37 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹137 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.
Net Income was ₹131 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹164 Mil.
Total Receivables was ₹168 Mil.
Revenue was ₹1,010 Mil.
Gross Profit was ₹628 Mil.
Total Current Assets was ₹549 Mil.
Total Assets was ₹1,194 Mil.
Property, Plant and Equipment(Net PPE) was ₹389 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹36 Mil.
Selling, General, & Admin. Expense(SGA) was ₹72 Mil.
Total Current Liabilities was ₹166 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(121.389 / 1036.556) / (168.131 / 1009.735)
=0.117108 / 0.16651
=0.7033

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(628.432 / 1009.735) / (602.942 / 1036.556)
=0.622373 / 0.581678
=1.07

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (643.259 + 371.556) / 1292.123) / (1 - (548.61 + 389.15) / 1193.901)
=0.214614 / 0.214541
=1.0003

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1036.556 / 1009.735
=1.0266

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(36.466 / (36.466 + 389.15)) / (37.033 / (37.033 + 371.556))
=0.085678 / 0.090636
=0.9453

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 1036.556) / (72.333 / 1009.735)
=0 / 0.071636
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 137.436) / 1292.123) / ((0 + 165.685) / 1193.901)
=0.106364 / 0.138776
=0.7664

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(131.086 - 0 - 164.322) / 1292.123
=-0.025722

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Par Drugs and Chemicals has a M-score of -2.57 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.57 mean?
Par Drugs and Chemicals (NSE:PAR) has a Beneish M-Score of -2.57 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Par Drugs and Chemicals and its competitors. According to the industry distribution chart, Par Drugs and Chemicals ranks #397 out of 911 companies in the Drug Manufacturers industry, placing it in the top 43.6%.
Is Par Drugs and Chemicals' Beneish M-Score too high?
Par Drugs and Chemicals' current Beneish M-Score is -2.57. Based on the distribution chart, Par Drugs and Chemicals ranks #397 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Par Drugs and Chemicals has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Par Drugs and Chemicals' Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Par Drugs and Chemicals ranks #397 out of 911 companies for Beneish M-Score. This puts Par Drugs and Chemicals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Par Drugs and Chemicals and its competitors. Par Drugs and Chemicals's current Beneish M-Score is -2.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Par Drugs and Chemicals stock overvalued right now?
Based on GuruFocus' analysis, Par Drugs and Chemicals (NSE:PAR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹207.62, compared to a current price of ₹91.00 — trading 56.2% below its estimated fair value. The current Beneish M-Score is -2.57. Par Drugs and Chemicals' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Par Drugs and Chemicals (NSE:PAR), the current Beneish M-Score is -2.57 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Par Drugs and Chemicals (NSE:PAR) Overvalued in 2026?

Based on GuruFocus' analysis, Par Drugs and Chemicals stock appears to be undervalued. The current stock price of ₹91.00 is trading 56.2% below its estimated GF Value™ of ₹207.62. GuruFocus considers Par Drugs and Chemicals to be Significantly Undervalued.

Key valuation signals for NSE:PAR:

  • Beneish M-Score: -2.57
  • GF Value™: ₹207.62 vs. price of ₹91.00 (56.2% below fair value)
  • GF Score™: 74/100 with 2 warning signs

No single metric tells the full story. See the NSE:PAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Par Drugs and Chemicals Business Description

Address Gotri Vasna Road, 815, Nilamber Triumph, Vadodara, GJ, IND, 390007
Par Drugs and Chemicals Ltd manufactures active Pharmaceutical Ingredients (APIs) and fine chemicals, serving domestic and international markets. Specializing in essential magnesium-based compounds and other specialty chemicals such as Magnesium Hydroxide, Magnesium Trisilicate, Magnesium Carbonate, various grades of Magnesium Oxide, Dried Aluminum Hydroxide Gel, and Sucralfate USP, the Company produces high-quality bulk drugs used in the formulation of finished pharmaceutical products like tablets, capsules, and liquids. Committed to maintaining stringent quality standards and utilizing manufacturing processes, the Company plays a vital role in supplying reliable ingredients that ensure the safety, efficacy, and stability of pharmaceutical formulations internationally.
74GF Score

Get the complete analysis for NSE:PAR

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹91.00
Price
₹207.62
GF Value